These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3550604)

  • 1. [Structure and activity of anthracyclines].
    Lavelle F
    Pathol Biol (Paris); 1987 Jan; 35(1):11-9. PubMed ID: 3550604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer activity of anthracycline antibiotics and DNA condensation.
    Cera C; Palumbo M
    Anticancer Drug Des; 1990 Aug; 5(3):265-71. PubMed ID: 2400539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains.
    Shelton CJ; Harding MM; Prakash AS
    Biochemistry; 1996 Jun; 35(24):7974-82. PubMed ID: 8672501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
    Capranico G; Butelli E; Zunino F
    Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human heart cytosolic reductases and anthracycline cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
    IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
    Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
    J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
    Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of anthracyclines and synthetic hexanucleotides. Structural factors influencing sequence specificity.
    Rizzo V; Battistini C; Vigevani A; Sacchi N; Razzano G; Arcamone F; Garbesi A; Colonna FP; Capobianco M; Tondelli L
    J Mol Recognit; 1989 Nov; 2(3):132-41. PubMed ID: 2636902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
    Taatjes DJ; Gaudiano G; Resing K; Koch TH
    J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of anthracycline--DNA complexes by circular dichroism.
    Rizzo V; Penco S; Menozzi M; Geroni C; Vigevani A; Arcamone F
    Anticancer Drug Des; 1988 Aug; 3(2):103-15. PubMed ID: 3165639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence specificity in the binding of anti-tumour anthracyclines to DNA: a success of theory.
    Pullman B
    Anticancer Drug Des; 1991 May; 6(2):95-105. PubMed ID: 2039585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
    Studzian K; Wasowska M; Piestrzeniewicz MK; Wilmańska D; Szmigiero L; Oszczapowicz I; Gniazdowski M
    Neoplasma; 2001; 48(5):412-8. PubMed ID: 11845988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genotoxic and mutagenic activity of antineoplastic anthracyclines and their aglycones: study in two test-systems].
    Vasil'eva SV; Makhova EV; Efremenkova OV; Bartoshevich IuE
    Genetika; 1996 Feb; 32(2):233-9. PubMed ID: 8713623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of a new bisintercalating anthracycline antibiotic.
    Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
    J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.